Director of the Cancer Biology and Precision Medicine Program, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona

Rafael Rosell, MD, PhD; is Director of the Cancer Biology and Precision Medicine Program, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona; Head of Medical Oncology Dr Rosell Oncology Institute, Quirón Dexeus University Hospital, Barcelona; President and Founder, Pangaea Biotech, S.L., Barcelona; Founder and President of the Spanish Lung Cancer Group and Founder and President of the Molecular Oncology Research Foundation (MORe). He is involved in application of translational genetic research to the clinical setting and has implemented large-scale screening for EGFR mutations in lung cancer patients in Spain to select patients for treatment with EGFR inhibitors instead of chemotherapy. Dr. Rosell has authored over 600 articles published in peer-reviewed medical and scientific journals, and he has given more than 800 presentations at medical and scientific conferences around the world.

6 Selected publications

  1. Costa C, Molina MA, Drozdowskyj A, Giménez-Capitán A, Bertran-Alamillo J, Karachaliou N, Gervais R, Massuti B, Wei J, Moran T, Majem M, Felip E, Carcereny E, Garcia-Campelo R, Viteri S, Taron M, Ono M, Giannikopoulos P, Bivona T, Rosell R. “The Impact of EGFR T790M Mutations and BIM mRNA Expression on Outcome in Patients with EGFR-Mutant NSCLC Treated with Erlotinib or Chemotherapy in the Randomized Phase III EURTAC Trial”. Clin Cancer Res. April 1, 2014 20:2001-2010

  2. Molina-Vila MA, Bertran-Alamillo J, Gasco A, Mayo-de-las-Casas C, Sanchez-Ronco M, Pujantell-Pastor L, Bonanno L, Favaretto A, Cardona A,Vergnenegre A, Majem M, Massuti B, Moran T, Carcereny E,Viteri S, Rosell R. “Nondisruptive p53 Mutations Are Associated with Shorter Survival in Patients with Advanced Non–Small Cell Lung Cancer” Clinical Cancer Research 2014 Apr 2. [Epub ahead of print]

  3. Rosell R, Bivona TG, Karachaliou N. “Genetics and biomarkers in personalisation of lung cancer treatment.” Lancet. 2013 Aug 24;382(9893):720-31.

  4. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez J. M, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno M. A, Terrasa J, Muñoz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia-Campelo R, Robinet G, Rodriguez D, Lopez-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sanchez-Ronco M, Drozdowskyj A, Queralt C, de Aguirre I, Ramirez J. L, Sanchez J. J, Molina M. A, Taron M, Paz-Ares L. “Erlotinib versus chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial” Lancet Oncology 2012 Mar;13(3):239-246. Epub 2012 Jan 26.

  5. Rosell R, Molina M. A, Costa C, Simonetti S, Gimenez-Capitan A, Bertran-Alamillo J, Mayo C, Moran T, Mendez P, Cardenal F, Isla D, Provencio M, Cobo M, Insa A, Garcia-Campelo R, Reguart N, Majem M, Viteri S, Carcereny E, Porta E, Massuti B, Queralt C, de Aguirre I, Sanchez J. M, Sanchez-Ronco M, Mate J. L, Ariza A, Benlloch S, Sanchez J. J, Bivona T, Sawyers C, Taron M “Pre-treatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations.” Clin Cancer Research 2011;17:1160-1168

  6. Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, Majem M, Lopez-Vivanco G, Isla D, Provencio M, Insa A, Massuti B, Gonzalez-Larriba J. L, Paz-Ares L, Bover I, Garcia-Campelo R, Moreno M. A, Catot S, Rolfo C, Reguart N, Palermo R, Sanchez J. M, Bastus R, Mayo C, Bertran-Alamillo J, Molina M. A, Sanchez J. J, Taron M. “Screening for epidermal growth factor receptor mutations in lung cancer” N Engl J Med Sep 3rd, 2009; 361:958

Link to Medical Oncology. ICO Badalona